Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in the Netherlands

Osteoporosis International

Volumn 22, Issue 5, 2011, Pages 1537-1546

  Netelenbos, J C ^a   Geusens, P P ^b,c   Ypma, G ^d   Buijs, S J E ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d IQVIA   (United States)

Author keywords

Adherence; Compliance; Non persistence; Oral osteoporosis medication; Persistence

Indexed keywords

ACTOKIT; ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CALCIUM; COLECALCIFEROL; DIDROKIT; ETIDRONIC ACID; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DATA BASE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; NETHERLANDS; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; URBAN AREA; URBANIZATION; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG SUBSTITUTION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 79955468225     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1372-5     Document Type: Article

References (50)

1. U.S. Department of Health Services (2004) Bone health and osteoporosis: a report of the Surgeon General. U.S. Department of Health and Human Services, Rockville, MD, USA. http://www.surgeongeneral.gov/library/bonehealth.
2. TP Van Staa EM Dennison HG Leufkens C Cooper 2001 Epidemiology of fractures in England Bone 29 517 522 11728921 10.1016/S8756-3282(01)00614-7 (Pubitemid 33124293)
3. AN Tosteson RT Burge DA Marshall R Lindsay 2008 Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations Am J Manag Care 14 605 615 18778176
4. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 521 19190316 10.1001/jama.2009.50 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D
5. J Ryg L Rejnmark S Overgaard K Brixen P Vestergaard 2009 Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001 J Bone Miner Res 24 1299 1307 19257816 10.1359/jbmr.090207
6. TA Van Geel S van Helden PP Geusens, et al. 2009 Clinical subsequent fractures cluster in time after first fractures Ann Rheum Dis 68 99 102 18677009 10.1136/ard.2008.092775
7. Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, Winkens B, Brink P, van Helden S (2010) Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos Int (in press)
8. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 9875874 10.1001/jama.280.24.2077 1:CAS:528: DyaK1MXjsVWruw%3D%3D (Pubitemid 29014065)
9. DH Solomon J Avorn JN Katz JS Finkelstein M Arnold JM Polinski MA Brookhart 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419 16287772 10.1001/archinte.165.20.2414 (Pubitemid 41640855)
10. AC Feldstein D Weycker GA Nichols, et al. 2009 Effectiveness of bisphosphonate therapy in a community setting Bone 44 153 159 18926939 10.1016/j.bone.2008.09.006 1:CAS:528:DC%2BD1cXhsFahtLjF
11. P Kothawala E Badamgarav S Ryu, et al. 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 18053457 10.4065/82.12.1493 (Pubitemid 350211697)
12. JA Cramer A Roy A Burrell, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359 10.1111/j.1524-4733.2007.00213.x (Pubitemid 351160875)
13. E Seeman J Compston J Adachi, et al. 2007 Non-compliance: the Achilles' heel of anti-fracture efficacy Osteoporos Int 18 711 719 17245547 10.1007/s00198-006-0294-8 1:STN:280:DC%2BD2s3mt1Sksg%3D%3D (Pubitemid 46684777)
14. ES Siris PL Selby KG Saag, et al. 2009 Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3 S13 19187810 10.1016/j.amjmed.2008.12.002
15. Sabate E (2003) Adherence to long-term therapies: evidence for action. http://whqlibdoc.who.int/publications/2003/9241545992.pdf.
16. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 16079372 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D (Pubitemid 41127293)
17. M Hiligsmann V Rabema HJ Gathon O Ethgen JY Reginster 2010 Potential clinical and economic impact of nonadherence with osteoporosis medications Calcif Tissue Int 86 202 210 20205345 10.1007/s00223-009-9329-4 1:CAS:528:DC%2BC3cXit1ahurg%3D
18. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 16330270 10.1016/j.bone.2005.10.022 (Pubitemid 44498580)
19. ES Siris ST Harris CJ Rosen, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 16901023 10.4065/81.8.1013 (Pubitemid 44175011)
20. F Lekkerkerker JA Kanis N Alasyed, et al. 2007 Adherence to treatment of osteoporosis: a need for study Osteoporos Int 18 1311 1317 17585359 10.1007/s00198-007-0410-4 1:STN:280:DC%2BD2srjtVensw%3D%3D (Pubitemid 47389473)
21. BA Briesacher SE Andrade RA Yood KH Kahler 2007 Consequences of poor compliance with bisphosphonates Bone 41 882 887 17707710 10.1016/j.bone.2007.07. 009 1:CAS:528:DC%2BD2sXhtF2htb3N (Pubitemid 47593009)
22. JR Curtis AO Westfall H Cheng E Delzell KG Saag 2008 Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday Osteoporos Int 19 1613 1620 18483689 10.1007/s00198-008-0604-4 1:STN:280:DC%2BD1cnksVCrsA%3D%3D
23. FJ Penning-van Beest JA Erkens M Olson 2008 Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis Curr Med Res Opin 24 1337 1344 18380910 10.1185/030079908X297358 1:CAS:528:DC%2BD1cXnsFOmtbs%3D (Pubitemid 351741565)
24. Imaz I, Zegarra P, Gonzalez-Enriquez J et al (2009) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int (in press)
25. MA Brookhart J Avorn JN Katz, et al. 2007 Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance Am J Med 120 251 256 17349448 10.1016/j.amjmed.2006.03.029 (Pubitemid 46341156)
26. DT Gold IM Alexander MP Ettinger 2006 How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy Ann Pharmacother 40 1143 1150 16735667 10.1345/aph.1G534 1:CAS:528: DC%2BD28XmsFyqt7w%3D (Pubitemid 43886973)
27. BA Briesacher SE Andrade H Fouayzi KA Chan 2008 Comparison of drug adherence rates among patients with seven different medical conditions Pharmacotherapy 28 437 443 18363527 10.1592/phco.28.4.437 (Pubitemid 351466455)
28. H Buurma ML Bouvy PAGM De Smet, et al. 2008 Prevalence and determinants of pharmacy shopping behaviour J Clin Pharm Ther 33 17 23 18211612 10.1111/j.1365-2710.2008.00878.x 1:STN:280:DC%2BD1c%2FlslWhuw%3D%3D
29. R Sikka F Xia RE Aubert 2005 Estimating medication persistency using administrative claims data Am J Manag Care 11 449 457 16044982 (Pubitemid 41022729)
30. RR Recker R Gallagher PE MacCosbe 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 80 856 861 16007889 10.4065/80.7.856 (Pubitemid 40911458)
31. JA Cramer S Silverman 2006 Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem Am J Med 119 S12 S17 16563936 10.1016/j.amjmed.2005.12.018
32. DW Hosmer S Lemesbow 1980 Goodness of fit tests for the multiple logistic regression model Commun Stat A10 1043 1069 10.1080/03610928008827941
33. FJ Penning-van Beest WG Goettsch JA Erkens RM Herings 2006 Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis Clin Ther 28 236 242 16678644 10.1016/j.clinthera.2006.01.002 1:CAS:528:DC%2BD28Xmtl2ltrg%3D (Pubitemid 44287822)
34. FJ Penning-van Beest JA Erkens M Olson 2008 Loss of treatment benefit due to low compliance with bisphosphonate therapy Osteoporos Int 19 511 517 17874028 10.1007/s00198-007-0466-1 1:STN:280:DC%2BD1c7nvFWqtw%3D%3D
35. V Rabenda R Mertens V Fabri, et al. 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 17999022 10.1007/s00198-007-0506-x 1:CAS:528:DC%2BD1cXltFyjurs%3D
36. E Landfeldt F Borgstrom S Robbins, et al. 2010 Adherence to treatment of osteoporosis in Sweden: the Swedish Adherence Register Analysis (SARA) Osteoporos Int 21 Suppl1 S252
37. CHA Van den Boogaard NS Breekveldt-Postma SE Borggreve, et al. 2006 Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 1757 1764 16968579 10.1185/030079906X132370 (Pubitemid 44449232)
38. JS McCoombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 10.1016/j.maturitas.2004.02.005 (Pubitemid 38781153)
39. EMEA recommends changes in the product information for protelos/osseor due to the risk of severe hypersensitivity reactions (2007). http://www.ema.europa.eu/humandocs/PDFs/EPAR/protelos/PressRelease-Protelos- 41745807en.pdf.
40. A Cooper J Drake E Brankin, et al. 2006 Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study Int J Clin Pract 60 896 905 16800837 10.1111/j.1742-1241.2006.01059.x 1:CAS:528:DC%2BD28XpvVemsLg%3D (Pubitemid 44082279)
41. TW Weiss SC Henderson CA McHorney JA Cramer 2007 Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills Curr Med Res Opin 23 2193 2203 17686228 10.1185/030079907X226069 (Pubitemid 350246605)
42. PP Geusens WF Lems HJ Verhaar G Leusink S Goemaere H Zmierczack J Compston 2006 Review and evaluation of the Dutch guidelines for osteoporosis J Eval Clin Pract 12 539 548 16987116 10.1111/j.1365-2753.2006.00647.x (Pubitemid 44427286)
43. HP McDonald AX Garg RB Haynes 2002 Interventions to enhance patient adherence to medication prescriptions: scientific review JAMA 288 2868 2879 12472329 10.1001/jama.288.22.2868 (Pubitemid 35425073)
44. T Gleeson MD Iversen J Avorn, et al. 2009 Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Osteoporos Int 20 2127 2134 19499273 10.1007/s00198-009-0976-0 1:STN:280:DC%2BC3c7mslOqtQ%3D%3D
45. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123 15001596 10.1210/jc.2003-030501 1:CAS:528:DC%2BD2cXisVWrtbo%3D (Pubitemid 38368399)
46. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe, et al. 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 17244788 10.1210/jc.2006-1526 1:CAS:528:DC%2BD2sXksVSrsbc%3D (Pubitemid 46556401)
47. DH Solomon T Gleeson M Iversen, et al. 2010 A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial Osteoporos Int 21 137 144 19436935 10.1007/s00198-009-0951-9 1:STN:280:DC%2BD1MjptlWhsQ%3D%3D
48. M Rossini G Bianchi O Di Munno, et al. 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 16 914 921 10.1007/s00198-006-0073-6 (Pubitemid 43781506)
49. JD Ringe G Moller 2009 Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis Rheumatol Int 30 213 221 10.1007/s00296-009-0940-5 1:CAS:528:DC%2BD1MXhsVajt7jK
50. O Sheehy CM Kindundu M Barbeau, et al. 2009 Differences in persistence among weekly different oral bisphosphonate medications Osteoporos Int 20 1369 1376 19020921 10.1007/s00198-008-0795-8 1:CAS:528:DC%2BD1MXotlyhu7w%3D